Roche's KRAS Drug Shows Promising Results in NEJM Study
TL;DR Summary
Roche has published Phase I data on its KRAS G12C inhibitor in the New England Journal of Medicine, showcasing its potential as a monotherapy across various cancers. The study included 137 patients with non-small cell lung cancer, colorectal cancer, and other solid tumors, as Roche aims to catch up with and surpass competitors Amgen and Mirati in the KRAS race.
- Roche publishes PhI data for KRAS drug in NEJM paper as it chases Amgen, Mirati Endpoints News
- Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation | NEJM nejm.org
- Novel KRAS Inhibitor Leads to Durable Responses in Multiple Tumor Types Medpage Today
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
53%
127 → 60 words
Want the full story? Read the original article
Read on Endpoints News